Abstract: An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

Abstract: The present invention discloses a saury Maillard peptide with antihyperuricemic activity and its preparation method and application, with the method comprising the following steps: mincing a saury, adding water, heating, agitating, adjusting a pH value to 4.2, separating by centrifugation, and collecting the precipitate; adding water, proteases and amino acids to the precipitate, adjusting a pH value to 7.0, hydrolyzing, adding a reducing sugar to cause a reaction, centrifuging and collecting a supernatant which is saury Maillard peptide; and spray drying the peptide liquid to obtain a dry powder. The method of the present invention realizes the continuous action of enzymolysis and Maillard reaction to prepare the Maillard peptide, not only simplifying the production process, shortening the production cycle, and reducing the production costs, but also significantly enhancing the antihyperuricemic activity of the produced Maillard peptide.

Abstract: A method for making a skin care composition by identifying connections between cosmetic agents and genes associated with one or more skin aging conditions. The method includes accessing a plurality of instances and at least one skin aging gene expression signature, comparing the at least one skin aging gene expression signature to the plurality of the instances, assigning a connectivity score to each instance based on the comparison and incorporating the cosmetic agent into a skin care composition when the connectivity score of the instance associated with the cosmetic agent has a negative correlation.

Abstract: The invention relates to methods, compositions, and kits for treating a condition with an immune response modifier and a human papillomavirus (HPV) vaccine. Conditions treatable with the methods, kits and compositions include but are not limited to neoplasia, anal intraepithelial neoplasia, high-grade squamous intraepithelial neoplasia, dysplasia, anal dysplasia, dysplastic lesion, high-grade dysplastic lesion, condyloma, anal cancer, anal tumor, HPV infection, and any HPV-induced condition.

Abstract: The present invention relates, according to some embodiments, method of treating eye diseases, such as AMD by administering Semaphorin 3C (Sema3C) or a variant thereof having amino acid modifications at furin-like pro-protein convertase cleavage sites, rendering these sites resistant to cleavage.

Abstract: Disclosed here are peptides derived from a serpin reactive center loop that have anti¬inflammatory, anti-atherogenic and anti-sepsis activity. Compositions containing such serpin-derived peptides are therefore useful in the treatment of transplant vascular disease and also for the treatment of hemorrhagic viral infections as well as lethal viral, fungal or bacterial sepsis in patients.

Abstract: An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.

Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

Abstract: The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a Smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.

Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.

Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.

Abstract: Methods of treatment of conditions or diseases associated with myeloid differentiation primary response (MYD88) protein using a selective HCK inhibitor are provided herein.

Abstract: The iCP-RF recombinant protein of present invention could mediate generation of the induced pluripotent stem cells (iPSCs) from terminally differentiated somatic cells.

Abstract: The invention relates to an antimicrobial surface, in particular a surface functionalised with a peptide comprising an antimicrobial moiety. The invention comprises a surface functionalised with a peptide comprising an antimicrobial moiety and a binder moiety, wherein the peptide is immobilized on the surface by electrostatic interactions between the binder moiety and the surface. Further provided is a medical device, a peptide and a method for the immobilization of a peptide.

Abstract: Certain embodiments are directed to methods and compositions for preventing treating bacterial infections. In certain embodiments the compositions comprise thioredoxin deficient bacteria.

Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.

Abstract: A composition that can solvate biofilms and disrupt bacterial cell walls acts to both kill the bacteria by cell lysis and remove the biofilm. This solvent-containing composition is effective against a broad spectrum of microbes and can be used on a variety of surfaces, both living and inanimate. The polarity of the solvent component of the composition is lower than that of pure water so that the composition exhibits increased efficacy in solvating the macromolecular matrix of a biofilm and in penetrating bacterial cell walls.

Abstract: The invention relates to a multilayered nanoparticle for delivery of RNA to a cell and methods of manufacturing and using the same. The multilayered nanoparticle has a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the at least one of the negatively charged polymer layers is RNA.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease or a condition related to angiogenesis. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to angiogenesis, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. Also disclosed herein are methods of treating and/or preventing a disease, disorder and/or a condition related to inflammation, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Abstract: A set of information including manually entered health-related data for a user, automatically collected health-related data for the user, and test results for the user may be received. In response to receiving the set of information, the manually entered health-related data for the user, the automatically collected health-related data for the user, and the test results for the user may be integrated into a comprehensive health profile for the user. Upon a request made on behalf of the user, at least part of the comprehensive health profile may be provided to the user.

Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.

Abstract: Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7.

Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.

Abstract: A pharmaceutical composition for preventing or treating arthritis, which comprises synthetic polypeptides; injections for preventing or treating arthritis; and a pharmaceutical composition for inducing differentiation of cartilage cells are described herein. Synthetic polypeptides of the present invention consisting of a polypeptide represented by SEQ ID NO: 1 and a polypeptide represented by SEQ ID NO: 2 have activity for recruiting stem cells to an arthritis region, inhibit apoptosis of cartilage cells, and exhibit anti-inflammatory activity and activity for promoting regeneration of cartilage cells. Thus, unlike a conventional arthritis treatment agent, the synthetic polypeptides can improve cartilage damage, can inhibit degenerative changes per se and can, at the same time, exhibit an effect as a stem cell treatment agent, and thereby can be usefully utilized as an arthritis prevention or treatment agent.

Abstract: The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.

Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.

Abstract: Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).

Abstract: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.

Abstract: The present invention relates to a skin administration system capable of improving the efficiency of skin delivery of an ingredient for controlling release of neurotransmitters and, particularly, to a microneedle containing an ingredient for controlling release of neurotransmitters.

Abstract: A composition for prevention or treatment of pulmonary fibrosis comprising chromenone derivatives represented by Formula I of the present invention or pharmaceutically acceptable salts thereof as an active ingredient, produces altered heat shock protein 27 (HSP27) dimers, thereby preventing normal HSP27 non-phosphorylated polymers from performing a chaperone function and reducing a cell protection function that chaperone originally performs. Thus the inventive composition has a remarkable inhibitory effect on pulmonary fibrosis, in particular, an irradiation-induced pulmonary fibrosis phenomenon.

Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.

Abstract: The present invention relates to at least one agent capable of increasing the level of one or more miRNA in a cell or cells of a subject, said miRNA comprising the sequence UUCCCUU, for use in the treatment and/or prevention of a retinal dystrophy, in particular characterized by photoreceptor degeneration, relative pharmaceutical compositions, nucleic acids, vectors and host cells.

Abstract: The present invention provides a compound having the structure:

Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer.

Abstract: The present invention involves preparing compounds represented by the following formula: from a compound of the following formula: In these formulae: R1 represents a Br group, an iodine group, a Cl group, an NO2 group, or an NH2 group; R2 represents a halogen group, an NO2 group, an NH2 group, Sn(R6)3, N?N—NR7R8, OSO2R9, N R10R11, phenyliodonium, a heterocyclic group iodine, boric acid, or a borate ester; R30 represents a protective group PG1; R40 or R50 represent hydrogen, a protective group PG2, or C6H5(C6H5)C?N, in which NR40R50 are together.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are described: AA1-Arg-Val-AA4-AA5-His-Pro-AA8-OH??(I), in which AA1, AA4, AA5, and AA8 are defined in the specification. The compounds of formula (I) can be used to treat hypertension (e.g., hypertension induced by pregnancy), preeclampsia, or a renal disease induced by pregnancy.

Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

Abstract: A leptin active peptide having CD-loop and helix E region mutations, a coding gene thereof, and an application thereof are provided in the present invention. An amino acid sequence of the leptin active peptide having CD-loop and helix E region mutations is shown in SEQ ID NO.1.

Abstract: Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.

Abstract: A leptin active peptide having helix D region mutation, a coding gene thereof, and an application thereof are provided in the present invention. An amino acid sequence of the leptin active peptide having helix D region mutation is shown in SEQ ID NO.1.

Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.

Abstract: The disclosure provides methods for resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a patient based on the cytological detection of antibody binding to telomerase in clinically relevant cells in the sample, wherein binding of the antibody to clinically relevant cells indicates the presence of malignant or cancerous cells.

Abstract: A transdermal formulation which can be applied to the skin as a latex-free hypoallergenic adhesive patch or transdermal delivery cream using a combination of glutathione, Vitamin D, glycol, sodium bicarbonate and base cream resilient in the presence of a wide range of drugs while increasing permeation of active antioxidant agents, water, isopropyl myristate, polyoxyethylene sorbitan monooleate, isopropyl palmitate, ascorbic acid, and dimethyl sulfoxide. The dosage amount can create in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain with increases by at least 10 percent of the ability of skin to retain moisture and totally absorb the glutathione without requiring injection or oral supplementation of the glutathione.

Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.

Abstract: Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an ?,?-disubstituted amino acid, or may comprise a crosslinker linking the ?-positions of at least two amino acids or at least one of said two amino acids may be an ?,?-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex.

Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.

Abstract: Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.